|
Accueil > Actualité
Bayer: applies to market fineronone in Japan
(CercleFinance.com) - Bayer announces the submission of a marketing authorization application to the Japanese Ministry of Health for finerenone in chronic heart failure with a left ventricular ejection fraction (LVEF) ≥40%.
This treatment, a selective non-steroidal mineralocorticoid receptor antagonist, demonstrated cardiovascular benefits in this indication in the phase III FINEARTS-HF study. Already marketed under the names Kerendia or Firialta, it is approved for chronic kidney disease associated with type 2 diabetes in over 90 countries. The application is based on positive data from FINEARTS-HF and is part of the MOONRAKER program, which includes over 15,000 patients. Similar submissions are underway in China, the USA and the EU. Copyright (c) 2025 CercleFinance.com. All rights reserved. |
21/02/2025 17:32
ADPpoursuit son repli, l'avis d'un analyste 21/02/2025 17:06 Rolls-Roycecontrat d'achat d'électricité avec SWU 21/02/2025 16:41 Airbusle satellite 'Biomass' de l'ESA en route pour Kourou 21/02/2025 16:30 KKRinvestit dans un complexe de logements à Stockholm 21/02/2025 15:45 Engiela Commission européenne approuve une aide d'Etat 21/02/2025 15:35 Repsolplombé par une dégradation de broker Tous les articles sociétés |
